Associated Papers
Common epidermal growth factor receptor mutations in north Indian patients with non-small cell lung carcinoma: evidence from real-time polymerase chain reaction.
Behera R et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace, 2025
Whole-Exome Sequencing Reveals Novel Candidate Driver Mutations and Potential Druggable Mutations in Patients with High-Risk Neuroblastoma.
Nokchan N et al.
Journal of Personalized Medicine, 2024
A good response to furmonertinib fourth-line treatment of an advanced lung adenocarcinoma patient with EGFR exon20in and PIK3CA mutation: a case report and literature review.
Sun K et al.
Frontiers in Oncology, 2024
Biomarker testing in lung cancer: from bench to bedside.
Batra U et al.
Oncology Reviews, 2024
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.
Laface C et al.
Pharmaceutics, 2023
Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers.
Kolesar J et al.
Molecular Cancer, 2022
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFRT790M-Mutant NSCLC.
Park HR et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2021
FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth.
Niu M et al.
Nature Communications, 2021
Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective.
Zhu J et al.
Pharmaceutics, 2021
Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC.
Yan Y et al.
Clinical Lung Cancer, 2020
Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients.
Ruan X et al.
Oncology Letters, 2020
Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D et al.
Thoracic Cancer, 2020
Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report.
Zhang Y et al.
Oncotargets and Therapy, 2019
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.
O'Kane GM et al.
Current Oncology (toronto, Ont.), 2018
The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer.
Zhang YC et al.
Journal of Hematology & Oncology, 2017
EGFR G796D mutation mediates resistance to osimertinib.
Zheng D et al.
Oncotarget, 2017
Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.
Nukaga S et al.
Cancer Research, 2017
Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA.
Offin M et al.
Journal of Oncology, 2017
Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
Barnes TA et al.
Frontiers in Oncology, 2017
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
Santarpia M et al.
Lung Cancer (auckland, N.z.), 2017
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.
Liao BC et al.
Journal of Biomedical Science, 2016
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Chabon JJ et al.
Nature Communications, 2016
Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line.
Sullivan I et al.
Frontiers in Medicine, 2016